CAR-T for Chronic Lymphocytic Leukemia Hits Goal of Mid-Stage Trial
(MedPage Today) -- A single infusion of the chimeric antigen receptor (CAR) T-cell product lisocabtagene maraleucel (liso-cel; Breyanzi) was shown to induce complete response or remission in patients with relapsed or refractory chronic lymphocytic...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news
More News: Cancer & Oncology | Chronic Leukemia | Chronic Lymphocytic Leukemia | Hematology | Leukemia